Kyntra Bio
KYNB
156 hedge funds and large institutions have $817M invested in Kyntra Bio in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 53 increasing their positions, 53 reducing their positions, and 26 closing their positions.
34% more call options, than puts
Call options by funds: $4.27M | Put options by funds: $3.18M
0.06% more ownership
Funds ownership: 2.86% → 2.92% (+0.06%)
0% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 53
4% less funds holding
Funds holding: 162 → 156 (-6)
13% less capital invested
Capital invested by funds: $935M → $817M (-$118M)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$29.3M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$15.3M |
| 3 |
Renaissance Technologies
New York
|
+$8.21M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.86M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$6.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$25.6M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.73M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.78M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$4.85M |
| 5 |
Goldman Sachs
New York
|
-$4.65M |
KYNB Hedge Fund Activity: Q1 2022 in Review
156 of the 6,359 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2022, worth a combined $817M — down 13% from $935M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of KYNB and 22 opened new positions — a net loss of 4 holders — while 53 trimmed existing stakes and 53 added.
The largest buyer was Point72 Asset Management, adding an estimated $29.3M. The largest seller was First Trust Advisors, cutting an estimated $25.6M.
- 156 institutional investors held Kyntra Bio (KYNB) as of Q1 2022, down from 162 in Q4 2021.
- Funds reported $817M of Kyntra Bio stock for Q1 2022, down 13% quarter-over-quarter.
- 22 funds opened new Kyntra Bio positions in Q1 2022 and 26 closed out, a net change of -4 holders.
- The largest Kyntra Bio buyer in Q1 2022 was Point72 Asset Management, an estimated $29.3M added.
- The largest Kyntra Bio seller in Q1 2022 was First Trust Advisors, an estimated $25.6M sold.
Based on aggregated 13F filings for Q1 2022.